We are not aware of any RRCTs that are completed, ongoing or being planned in the field of diabetes (https://clinicaltrials.gov; accessed 31 Jan 2022) except for the SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST) trial (EudraCT 2019-001046-17, Clinicaltrials.gov NCT03982381) [34]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.